Skip to content
Triangle logo TriangleGet started
← Transplant-Related Carcinoma

NCT02619682 · STUDY IN CONTEXT

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Adverse events Toxicity during the 24 months plus one month of post autologous transplant maintenance therapy

Source null

→

secondary · POSTED

all MM patients who got post autologous transplant study therapy

Source null

→

secondary · POSTED

Disease Free Survival

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-transplant-related-carcinoma
nct id
NCT02619682
trial label
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
3
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-transplant-related-carcinoma
    nct id
    NCT02619682
    outcome key
    om-0000
    source section id
    NCT02619682-om-0000
    source outcome index
    0
    endpoint
    Number of Participants With Adverse Events, Graded According to CTCAE Version 4.0
    endpoint definition
    Adverse events Toxicity during the 24 months plus one month of post autologous transplant maintenance therapy
    time origin
    2 years plus one month
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-transplant-related-carcinoma
    nct id
    NCT02619682
    outcome key
    om-0001
    source section id
    NCT02619682-om-0001
    source outcome index
    1
    endpoint
    Overall Survival
    endpoint definition
    all MM patients who got post autologous transplant study therapy
    time origin
    Median 4.6 years from start of therapy
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-transplant-related-carcinoma
    nct id
    NCT02619682
    outcome key
    om-0002
    source section id
    NCT02619682-om-0002
    source outcome index
    2
    endpoint
    Disease Free Survival
    endpoint definition
    Disease Free Survival
    time origin
    Median of 4.6 years from start of study therapy
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-transplant-related-carcinoma
    nct id
    NCT02619682
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Post Autologous Transplant Maintenance
    regimen
    one arm = all enrolled MM patients got post autologous transplant maintenance therapy
    analyzed count
    30
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02619682-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-transplant-related-carcinoma
    nct id
    NCT02619682
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Post Autologous Transplant Maintenance
    regimen
    one treatment arm all patients enrolled on study
    analyzed count
    30
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02619682-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-transplant-related-carcinoma
    nct id
    NCT02619682
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Post Autologous Transplant Maintenance
    regimen
    one treatment arm all patients enrolled on study
    analyzed count
    30
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02619682-om-0002#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-transplant-related-carcinoma
    nct id
    NCT02619682
    harm key
    EG000
    source section id
    NCT02619682-ae
    event group key
    EG000
    event group label
    Post Autologous Transplant Maintenance
    serious affected
    4
    serious at risk
    30
    other affected
    30
    other at risk
    30
    frequency threshold
    3.3
    collection period
    Median 4.6 years from start of therapy
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice